Tests time-restricted eating for kidney health in adults with type 2 diabetes
Tests a daily 8-10 hour eating window in adults with diabetes and protein in urine.
Key facts
- Who runs it
- University of California, San Diego
- Where
- La Jolla, United StatesSee the site
- Trial code
- Registry title
- Time Restricted Eating in Patients With Microalbuminuria
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 25 people, planned
- Started
- Jul 2026
- Expected to end
- Feb 2028
- Type of study
- Interventional
- Treatments tested
- Time Restricted Eating
- Record updated
- 14 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with type 2 diabetes and a small amount of protein in the urine. Everyone eats only within an 8-10 hour window each day.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with A1c between 6.5 and 9.0 % (48–75 mmol/mol), urine albumin creatinine ratio (uACR) ≥ 30 - 300 mg, and eGFR above 45.
- Earlier treatment
- Must be on stable doses of medications. People on GLP-1 receptor agonists must have taken a consistent dose for at least 3 months. People on heart medications cannot have dose changes during the study. Cannot join if taking insulin or sulfonylureas.
- Biomarker or test result
- A1c between 6.5 and 9.0 % (48–75 mmol/mol); uACR ≥ 30 - 300 mg; eGFR above 45.
Main reasons for not taking part
- Type 1 diabetes, insulin or sulfonylurea use, or A1c above 9 % (75 mmol/mol)
- eGFR below 45, stage 4 or 5 chronic kidney disease, or dialysis
- Pregnant or breastfeeding
- Eating disorder, weight-loss program or weight-loss surgery
- Heart attack, stroke or similar heart event in the past year
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Age: 18-75 years old
- Participants with T2DM with A1c between 6.5 and 9.0 % and on stable doses of medications who are weight-bearing and self-ambulatory
- uACR ( urine albumin creatinine ratio) results ≥ 30 - 300 mg
- Willingness to use smartphone for research procedures (Apple iOS or Android OS)
- Baseline eating period ≥12 hours/day and sufficient logging on the mCC app
- Person of childbearing potential will be given a pregnancy test on study enrollment and asked to use contraception throughout the study
- Post-menopausal and individuals on hormone replacement therapy will be included
- Estimated Glomerular Filtration Rate (EGFR) > 45
- If participants are on cardiovascular medications (HMG CoA reductase inhibitors (statins), other lipid-modifying drugs, anti-hypertensives) no dose adjustments will be allowed during the study period
- Participants on stable doses (consistent dose for ≥3 months) of GLP-1 receptor agonists will be included
Who cannot take part
- Systolic BP greater than 160 mmHg and/or Diastolic BP greater than 110 mmHg (with or without treatment/medication)
- Active tobacco or illicit drug use
- Currently on a special or prescribed diet for other reasons (e.g., Celiac disease),
- On recently prescribed medication that is meant for weight loss, or has known effect on appetite suppression ( patient on stable dose for 3 months can be enrolled )
- History of eating disorder(s)
- History of surgical intervention for weight management (e) active eating disorder
- Treatment for active inflammatory and/or rheumatologic disease and cancer
- A major adverse cardiovascular event within the past 6 months such as acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)
- History of Uncontrolled arrhythmia (i.e., rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria) 18. Liver cirrhosis and/or significant alterations in liver function
- History of (a) thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion), Shift workers with variable (e.g., nocturnal) hours
- History of major adverse cardiovascular events within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA))
- History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion)
- History of adrenal disease
- History of malignancy undergoing active treatment, except non-melanoma skin cancer
- Known history of type I diabetes
- History of stage 4 or 5 chronic kidney disease or requiring dialysis
- History of HIV/AIDS
- Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness)
- Participants with Type1DM and T2DM who are taking insulin, sulfonylureas, or have an HbA1c > 9 %
- Estimated Glomerular Filtration Rate (EGFR) < 45
- LDL cholesterol greater than 200 mg/dL
- Triglycerides greater than 500 mg/dL
- Chronic kidney disease with an eGFR calculated based on the Modification of Diet in Renal Disease (MDRD) equation <50mL/min/1.73m2
- Pregnant or breastfeeding individuals
- Currently enrolled in a weight-loss or weight-management program,
- Caregivers for dependents requiring frequent nocturnal care/sleep interruptions
- More than one trip planned to travel to a time zone with greater than a 3-hour difference during study period
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Altman Clinical and Translational Research InstituteLa Jolla, United StatesContact: Gavin McLaren, BATaking people
About the trial
What the trial wants to find out
This is a clinical trial to assess how time-restricted eating (TRE) may improve kidney health and filtration patients with type 2 diabetes and increased protein content in their urine. All participants will be participating in TRE in which they follow a consistent 8-10 hour eating window everyday.
The group in the trial
- Time Restricted Eating (TRE) GroupTreatment being tested
Participants will limit the number of hours they eat in a dat to an 8-10 window and will also receive the standard heath and nutritional wellness guidelines. They will also be required to log food entries through the use of a smartphone app. Patients will also be required to wear a continuous glucose monitor (CGM) for the first and last two weeks of the 14 trial.
Treatment: Time Restricted Eating
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Time-Restricted Eating (TRE) on Kidney Health (The TREK Study)
- Plain-language title
- Tests time-restricted eating for kidney health in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06884059, who can take part
- Record updated
- 14 July 2026